---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-141087"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2025-06-16T23:59:59+00:00"
generated_at: "2026-05-19T06:34:10.388431+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Intellia reports 98% reduction in HAE attacks with lonvo-z over 3 years in Phase 1

## Summary
- Single dose led to mean 98% reduction in monthly HAE attack rate across all 10 patients.
- All patients attack-free and treatment-free for median 23 months at data cutoff.
- No treatment-emergent serious adverse events; infusional reactions mostly Grade 1, all resolved.
- Phase 3 HAELO trial screening completed ahead of schedule; >50% screened in U.S.
- Expects BLA submission in 2026 and U.S. launch in 2027, pending FDA approval.

## SEC filing metadata
- accession: 0001193125-25-141087
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2025-06-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312525141087/0001193125-25-141087-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312525141087/d82485d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-141087
- JSON: https://secwatch.observer/filing/0001193125-25-141087.json
- Plain text: https://secwatch.observer/filing/0001193125-25-141087.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.